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Adverse effects of medications that occur at low
frequency or low severity are often not detected
in the current framework of drug approval and
monitoring. Of particular concern are potential
behavioral consequences such as depression or cog-
nitive dysfunction that may occur from commonly
prescribed medications. This study explores the use
of measuring daily affect, both positive and nega-
tive, as a method for detecting clinically relevant
affective toxicity from medications commonly pre-
scribed to older adults. Findings from this study
suggest that metoclopramide may have the poten-
tial for causing significant changes in affect among
healthy elderly adults. This may suggest that more
vulnerable or disabled adults may be at even
greater risk for affective changes related to this
medication. 
he Institute of Medicine has recently
called for a greater emphasis on postmarketing
research in order to improve the detection of adverse
effects of medications that occur at a low incidence or
occur when medications are used for a longer dura-
tion or at a higher dose than intended.
1 Morrison and
Katz have previously suggested that the current pro-
cedures for recognizing adverse effects of new drugs
are designed to identify effects that are serious and
common.
2 However, these procedures are conducted
predominantly in young and middle-aged populations
of adult subjects and may not be adequate to detect
side effects that are significant in the elderly. Of par-
ticular concern are central nervous system effects,
such as cognitive changes or affective disturbances,
which, unless explicitly examined, often go unnoticed
or ignored. As highlighted by a recent report from
the US General Accounting Office (GAO), the grow-
ing elderly population may be particularly vulnera-
ble to adverse drug reactions and is an issue that is
important to national health care policy as well as
clinical practice.
3 Moreover, the GAO report empha-
sizes that, even in the absence of serious injury, less
severe or persistent adverse reactions can decrease
the general quality of life of patients. In this context,
it is important to ask whether medications prescribed
commonly for older patients regularly cause impair-
ments in affect and/or cognitive functioning.
Previous research by Katz and colleagues has estab-
lished methodologies for the systematic examination
of the cognitive effects of medications in healthy
noncognitively impaired elderly adults.
4 This line of
investigation has demonstrated reproducible cognitive
impairment from medications such as oxybutynin and
has failed to demonstrate effects of other medications
such as cimetidine.
4,5We have now begun to extend this
methodology to include the systematic evaluation of
affective or mood disturbances related to commonly
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prescribed medications in nondepressed elderly adults.
The dopamine antagonist metoclopramide has been
reported in several case reports to cause or exacerbate
depressive symptoms.
6-9Although the magnitude of this
effect is not well known, the general impression that
dopamine antagonists cause affective toxicity suggests
that this agent may be particularly well suited to exam-
ine the sensitivity of the methods for detecting affec-
tive toxicity. The hypothesis for this research is that
measures of daily positive and negative affect are use-
ful in detecting clinically significant affective toxicity in
nondepressed elderly adults.
Methods
Strategies for recruitment and the inclusion/exclusion
criteria of this study were similar to those for an earlier
study involving repeated measures of cognitive per-
formance on normal volunteers.
5 Briefly,inclusion cri-
teria for subjects included:age 55 years or older,med-
ically stable (no hospitalizations or significant
medication changes within the previous month), cog-
nitively intact (Brief orientation-Memory-Concentra-
tion Test
10 score <3 and Mini-Mental State Examina-
tion score
11 >26), and euthymic (a 20-item Center for
Epidemiologic Studies Depression Scale score
12 <12).
Subjects were also required to have completed at least
8 years of school,learned English by age 6,and to have
vision/hearing adequate to complete the assessments.
Exclusion criteria included a history of central nervous
system disease, alcohol or substance abuse within the
past 5 years,mental retardation,schizophrenia,or bipo-
lar or psychotic disorders.Subjects were also excluded
if they were taking centrally acting medication(s) or
medications capable of causing drug-related cognitive
impairment, such as benzodiazepines, antihistamines,
antidepressants,antipsychotics,antispasmatics,lithium,
opioid analgesics, seizure medications, and digoxin.
Design
The study was conducted as two double-blind, placebo-
controlled randomized trials of metoclopramide (40
mg/day) administered daily for up to 5 weeks. Results
from an initial study (n=10) comparing placebo and
metoclopramide were pooled with results from a second
study (n=12) that randomized subjects to placebo,meto-
clopramide,or sertraline.Subjects randomized to the ser-
traline arm were not included in this report.The experi-
mental protocols were otherwise identical.After an ini-
tial screening examination and assessment for eligibil-
ity,each subject completed a daily affect diary for 1 week
prior to randomization.At the time of randomization,sub-
jects were started on either 10 mg/day of metoclopramide
or placebo.The dose of metoclopramide was increased by
10 mg per week until the final dose of 40 mg/day was
reached. Positive and negative affective state was mea-
sured during the placebo lead-in week and then daily for
5 weeks. Lawton's positive and negative daily affective
scale was used as the principal assessment instrument.
13,14
This scale has discriminate validity for both minor and
major depression among the elderly.
15
Subjects were seen weekly for safety and to monitor
medication compliance. In addition to pill counts,
riboflavin was added to the study medication to probe
for medication adherence.Riboflavin is a nonpsychoac-
tive vitamin that has been used in other investigations as
a check on medication compliance and is visually
detected in the subject's urine by the presence of fluo-
rescence under ultraviolet illumination.
Statistical analyses
For the analysis of drug effects, the random slope for
positive and negative affect were compared between
the placebo group and the metoclopramide group using
a linear mixed-model analysis. The average baseline
affective measure was controlled in the analysis. Base-
line characteristics were compared using standard t-tests
and chi-square analysis.
Results
The sample for the study consisted of 14 men and 8
women.There were few significant demographic differ-
ences between subjects in the metoclopramide (n=12)
and placebo (n=10) groups.The mean age [SD] of sub-
jects was 70.7 [5.2] (range 57 to 79) years (t=2.18,20 df,
P=0.830).The mean number of years of education [SD]
was 14.7 [2.8] (range 10 to 20) (t=3.72, 20 df, P=0.001)
and 59.1% of the subjects were married (χ
2=0.006,1 df,
P=0.937). Subjects were cognitively intact: mean score
[SD] on the Mini-Mental Status Examination was 28.9
[1.1];(range 26 to 30) (t=2.21,20 df,P=0.040),and were
without significant depression: mean score [SD] on the
(20-item) Center for Epidemiologic Studies - Depres-sion Scale 4.2 [2.0];(range 0 to 10) (t=1.08,20 df,P=0.294).
Compliance with recording of daily affect was 100%
during trial participation and greater than 90% for pill
compliance. Riboflavin results were consistent with
pill counts in all but one subject (placebo) who tested
negative for riboflavin on 3 of 5 occasions. Five sub-
jects did not complete the protocol.Four subjects com-
plained of lethargy/depression (3 on metoclopramide
and 1 on placebo) and one subject had scheduling dif-
ficulties (placebo) (χ
2=0.078, 1 df, P=0.781). All sub-
jects completed an average of 28.6 (SD: 6.8) days on
study medication with no difference between the two
groups (t=0.803, 20 df, P=0.432).
The primary outcome measures were the change over
time in measures of positive and negative daily affect.As
shown inTable I,there were no significant differences in
the slopes for the 2 groups for positive or negative affect.
One subject (metoclopramide) experienced an 18%
decrease in positive affect averaged over the last week of
medication compared with baseline.No subjects experi-
enced a significant increase in negative affect. Combin-
ing subjects who dropped out for psychiatric symptoms
with the subjects who experienced at least a 15%
decrease in positive affect resulted in 4 of 12 subjects in
the metoclopramide versus 1 of 10 subjects in the
placebo group experiencing significant affective toxicity
(χ
2=1.691,1 df,P=0.193).Change in positive affect from
baseline to the final week of study medication in the
remaining subjects ranged from an increase of 14.7% to
a decrease of 13.6% (t=0.675,16 df,P=0.509).
Discussion
As the goal of this investigation is to provide the most
sensitive methodology for detecting affective toxicity,it
is reasonable to explore both toxicity in the broader
sense that may affect all subjects who are exposed to a
given medication,and also whether particular patients or
patient groups are vulnerable to a given medication. In
order to explore the more global toxicity issues,we were
able to examine the aggregate slopes representing the
effect of metoclopramide.The results from this analysis
demonstrate that metoclopramide does not cause sig-
nificant reproducible decrements in positive or negative
affect in healthy older adults.
In order to enhance the sensitivity of detecting effects
for individuals,one must consider combining effects that
lead to study withdrawal with significant changes in indi-
viduals who are able to tolerate study completion.In this
study, the finding that 4 subjects in the metoclopramide
group and 1 in the placebo group withdrew from the
study due to lethargy/depressive symptoms or experi-
enced significant affective toxicity (33% of those on
metoclopramide versus 10% on placebo), suggests that
metoclopramide may cause significant affective toxicity
in individual subjects. Indeed, though the small sample
size of this study does not allow detection of a statistically
significant effect,this difference is potentially very signif-
icant clinically. Using methods developed by Cohen, a
study with 96 subjects would be predicted to reproduce
this finding with a power of 80% (128 subjects for 90%
power).
16
In addition to the limitations apparent by the small
sample size of each study group,there is the possibility
that the measures employed were insensitive to mea-
suring affective toxicity. Given that these data are
highly suggestive of an effect,concern for this is damp-
ened. In addition, combining study noncompletion
information with results from patients who do com-
plete the study,but have significant effects,introduces
the need to develop methods for selecting appropriate
parameters for defining the effect. Clearly, the choice
of at least a 15% decrement in positive affect from
baseline to completion is arbitrary and will need fur-
ther exploration.
In summary, studies on admittedly small samples of
older adults strongly suggest that certain healthy indi-
viduals may be particularly vulnerable to affective tox-
icity from metoclopramide.This supports the findings
from the several published case reports and empha-
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Table I. The slope for changes
in positive and nega-
tive affect over time
between the metoclo-
pramide and placebo
groups.
Slope Standard error P-value for group 
differences
• Positive affect Metoclopramide -0.0167 0.0173
Placebo -0.0223 0.0198 0.833
• Negative affect Metoclopramide -0.0116 0.0129
Placebo -0.0389 0.0149 0.941sizes the need to consider affective changes in healthy
as well as more debilitated adults. The findings
reported also support the further development of this
methodology for exploring behavioral consequences
of other commonly prescribed medications. ❏
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Exploracion de la toxicidad a nivel
afectivo de medicamentos de
prescripcion frecuente en sujetos de
edad avanzada
Hay medicamentos que pueden tener efectos secun-
darios poco frecuentes y de poca gravedad, los que
generalmente no son detectados a traves de la forma-
covigilancia. Los fármacos comúnmente prescritos en
sujetos de edad avanzada pueden provocar poten-
ciales consecuencias a nivel conductural como la
depresión o la disfunción cognitiva. Este estudio
unide los afectos diariamente, tanto los positivos
como los negativos,como un método para detectar la
“toxicidad afectiva”, clínicamente relevante, de
medicamentos comúnmente prescritos en sujetos de
edad avanzada. Los kallazgos de este estudio sugieren
que la metoclopramida puede tener la potencialidad de
causar cambios significativos en el afecto de sujetos de
edad avanzada sanos. Esto puede sugerir que los adul-
tos más vulnerables o más debilitados pueden tener un
mayor riesgo de cambios en los afectos relacionados con
este fármaco.
Exploration de la toxicité affective 
des médicaments couramment prescrits
chez le sujet âgé 
Les effets secondaires des médicaments qui sont peu
fréquents ou peu sévères ne sont pas souvent détectés
dans le cadre des procédures habituelles d’autorisa-
tion de mise sur le marché et de surveillance.Les effets
comportementaux potentiels, tels la dépression ou les
dysfonctionnements cognitifs,imputables aux médica-
ments couramment prescrits s’avèrent particulière-
ment intéressants.Dans cette étude,la mesure quotidi-
enne de l’affect, tant positif que négatif, est évaluée en
tant que méthode susceptible de détecter la toxicité
affective des médicaments couramment utilisés chez le
sujet âgé, dès lors qu’elle est cliniquement significa-
tive. Les résultats obtenus suggèrent que le métoclo-
pramide peut provoquer des modifications affectives
significatives chez le sujet âgé en bonne santé. De ce
fait, le risque d’un tel effet iatrogène pourrait être net-
tement plus élevé chez des malades, plus vulnérables
ou a fortiori handicapés.
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